On October 12, 2026 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported its participation at the 17th Annual World ADC Conference, taking place in San Diego, October 12-15, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Sutro’s presence at World ADC this year reflects meaningful progress across our pipeline, from a plenary presentation on the early clinical safety and pharmacokinetic profile of STRO-004 to new preclinical insights on STRO-006 and our first wholly-owned dual-payload ADC, STRO-227," said Hans-Peter Gerber, Ph.D., Sutro’s Chief Scientific Officer. "Notably, we look forward to sharing how the design principles that shaped STRO-004, along with our preclinical findings, are translating into its emerging clinical profile. Together, these presentations offer further evidence that our platform has the potential to deliver next-generation ADCs with a wider therapeutic index for complex targets and the ability to overcome resistance to single-payload ADCs."

Presentation/Panel Discussion Details:

Next-Generation High DAR TOPO1i x DDRi Dual-Payload ADCs to Improve Efficacy, Overcome Resistance & Enhance Safety
Presenter: Krishna Bajjuri, Ph.D.
Date/Time: October 12, 2026, 12:30PM PT

Plenary Session: Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design & Preclinical Characterization Links to Differentiated ADC Clinical Performance

Presenter: Daniel Calarese, Ph.D.
Date/Time: October 13, 2026, 9:30AM PT
Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance (Discovery Chemistry morning and afternoon sessions)
Sutro Participant (Chair): Krishna Bajjuri, Ph.D.
Date/Time: October 13, 2026, 11:00AM to 4:00PM PT
Driving Clinical Success With STRO-006: Breaking Down Insights From PDX Response & Translational Biomarkers
Presenter: Alice Yam, Ph.D.
Date/Time: October 13, 2026, 12:00PM PT

Panel: Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners?

Sutro Participant: Alice Yam, Ph.D.
Date/Time: October 13, 2026, 5:45PM PT

Breaking Down Preclinical Characterization of STRO-227 Dual Payload ADC to Evaluate Efficacy & Safety in ADC Resistance Models
Presenter: Daniel Calarese, Ph.D.
Date/Time: October 14, 2026, 2:30PM PT

Following the event, the content will be made available in the Scientific Publications section of Sutro Biopharma’s website at www.sutrobio.com.

(Press release, Sutro Biopharma, OCT 12, 2026, View Source [SID1234673328])

On October 12, 2026 Elicera Therapeutics AB (publ) reported that the Phase I part of the CARMA study has been completed. The study is evaluating the safety and preliminary efficacy of escalating doses of ELC-301, Elicera’s iTANK-armed CAR T-cell therapy, in patients with B-cell lymphoma who have no remaining curative treatment options. Eight of twelve patients achieved complete metabolic response (CMR), meaning no active disease, as their best response during the follow-up. Objective tumor response, i.e. a reduction in tumor burden, was observed in eleven patients. Six patients remained in CMR at their most recent assessment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Completing the dose-escalation part of the CARMA study is a major milestone for Elicera. What stands out isn’t just the high proportion of responding patients, but also the depth and durability of those responses in a population that had run out of viable treatment options. This includes patients who had relapsed after completed CAR T-cell therapy. Some patients in the study have now maintained their response for well over a year, which is an early but meaningful signal of durability. This strengthens our confidence in the potential of ELC-301 and the iTANK platform. We are now preparing for a full analysis of all the collected data from the Phase I part of the study, and patient recruitment to the Phase IIa part of the study, where we look forward to building further on these encouraging results," says Johan Liwing, CEO of Elicera Therapeutics.

"We’re encouraged to see responses and a safety profile that support continuing the clinical development of ELC-301. Every signal of efficacy matters enormously in this setting. The patients enrolled in this trial have no remaining curative treatment options and, given their disease stage, would typically face a very limited life expectancy. That these early results have been achieved in such a difficult-to-treat population makes them particularly meaningful as we now move into Phase IIa," comments Gunilla Enblad, professor at the Department of Immunology, Genetics, and Pathology, senior consultant in oncology at Uppsala University Hospital, and clinical principal investigator for the CARMA study.

Key highlights from the Phase I part of the CARMA study

Patients in the study have, in general, undergone extensive prior treatment, with several having received multiple lines of chemotherapy, stem cell transplantation and, in three cases, prior CAR T-cell therapy before entering the study.
All twelve patients in the Phase I dose-escalation part have now been treated and evaluated for preliminary efficacy at least at the one-month follow-up
No dose-limiting toxicities (DLT) have been observed across any of the three dose cohorts, and ELC-301 has continued to be well-tolerated.
Promising, deep and durable response rates were observed:

Complete metabolic response (CMR; no active disease): 67% (8/12 patients).
Overall response rate (ORR; objective tumor response): 92% (11/12 patients). Three of the twelve evaluated patients had previously received CAR T-cell therapy but subsequently relapsed. After treatment with ELC-301, all three achieved disease control, of whom two obtained an objective tumor response, including one CMR.
Disease control rate: 100% (12/12 patients).
Of the eight patients who have achieved CMR as their best response to date, six remain in CMR at their most recent assessment; two later progressed after initially responding.
One patient has confirmed CMR for at least 18 months. Another patient has confirmed CMR for at least 12 months.
ELC-301 is a fourth-generation CAR T-cell therapy targeting the CD20 antigen, armed with the company’s iTANK platform to activate a broader and more comprehensive parallel immune response against cancer.

The CARMA study is a clinical Phase I/IIa study evaluating the safety, optimal dosing, and preliminary efficacy of ELC-301 in patients with relapsed or refractory B-cell lymphoma who have undergone at least two previous lines of standard treatment and have no remaining curative treatment options. The study includes a dose-escalation phase (Phase I) with twelve patients across three cohorts to identify the maximum tolerated dose, followed by further evaluation of six patients in an expansion phase (Phase IIa).

The Swedish Medical Products Agency (Läkemedelsverket) has recently approved a substantial modification to the clinical trial authorization for the CARMA study, permitting the study to proceed into its Phase IIa part. Patient recruitment is expected to begin in Q4 2026.

(Press release, Elicera Therapeutics, OCT 12, 2026, View Source [SID1234673327])

On October 12, 2026 Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, reported an update on its intellectual property strategy, outlining progress on new method of use patents and plans to expand its portfolio with composition of matter protection for a modified "next generation" pelareorep. These initiatives build on the Company’s existing manufacturing patent protection through 2044 and are intended to extend protection for specified therapeutic uses and future innovations into the late 2040s, subject to patent issuance and applicable patent terms.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A new method of use patent covering pelareorep as an immunotherapy for the treatment of cancer has been issued in several countries, and the Company expects the corresponding U.S. patent to issue in the near term. This patent is part of Oncolytics’ strategy to protect pelareorep’s therapeutic applications alongside the proprietary processes used to manufacture it.

Oncolytics has three patent application families pending, including multiple method of use patents. The expanding portfolio addresses certain combination therapies, including pelareorep in connection with immunotherapies and targeted therapies, reflecting the Company’s strategy to develop pelareorep across complementary cancer treatment approaches.

This quarter, the Company expects to convert one of these pending applications into a U.S. application submitted with a request for Track One prioritized examination. This application is directed to the use of pelareorep as a therapy that induces immunologic responses. The U.S. Patent and Trademark Office’s Track One program provides prioritized examination with a goal of reaching a final disposition within approximately 12 months after prioritized status is granted. The program can accelerate examination and provide earlier clarity on the scope of potential patent protection, supporting clinical development and partnering decisions. Prioritized examination does not guarantee patent allowance.

In parallel, Oncolytics is working with an academic partner on a modified form of pelareorep that the Company refers to as "next generation" pelareorep. The Company expects this work to support the addition of a new composition of matter patent to its portfolio, with the potential for up to 20 years of patent protection measured from the applicable filing date. The modified pelareorep is being developed with the expectation that it could provide enhanced efficacy, which will require confirmation through further studies.

"We are expanding our patent portfolio to protect how pelareorep is manufactured, how it is used to treat cancer, and the innovations that could define its next generation," said Jared Kelly, Chief Executive Officer of Oncolytics. "Our existing manufacturing protection through 2044 provides a strong foundation. The additional method of use patents and potential new composition of matter protection are intended to extend that foundation into the late 2040s and support the long-term development and commercial potential of pelareorep."

The Company expects the new method of use patents, once issued, to provide protection for their covered therapeutic applications into the late 2040s. The scope and duration of protection will depend on the claims ultimately granted, applicable filing dates and jurisdiction-specific patent rules. The anticipated composition of matter patent would provide a separate layer of protection for the modified pelareorep.

About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.

(Press release, Oncolytics Biotech, OCT 12, 2026, View Source [SID1234673326])

On October 12, 2026 Bristol Myers Squibb (NYSE: BMY) reported positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met the primary endpoint with a statistically significant and clinically meaningful improvement in progression-free survival by blinded independent central review, and safety results consistent with the known RYZ101 safety profile. ACTION-1 is a randomized Phase 3 clinical trial evaluating RYZ101 (225Ac-DOTATATE) versus investigator’s choice of standard of care (high-dose or high-frequency long-acting somatostatin analogues, everolimus, or sunitinib) in patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed following Lutetium-177 (Lu177)-based therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The improvement in progression-free survival is a defining moment for RYZ101 and for the patients we built this program around — people with advanced GEP-NETs whose cancer has progressed after Lu177-based therapy and who have few remaining options," said Amreen Husain, MD, chief medical officer of RayzeBio. "This is the kind of impact we set out to deliver with actinium-based radiopharmaceuticals, and it is an important milestone supporting the pipeline we are building across our RPT platform. These are the first results from a Phase 3 trial of an alpha-isotope based targeted RPT (225Ac) in any indication, and we are moving with urgency to bring these data to the FDA and, ultimately, provide a novel option for patients."

The FDA granted RYZ101 Orphan Drug Designation for the treatment of GEP-NETs in August 2026 based on the significant unmet need facing patients with this disease. That designation, combined with the results of this interim analysis, supports RayzeBio’s continued development efforts and plans to engage with the FDA to discuss next steps toward a regulatory submission. Detailed results are expected to be presented at a future medical meeting.

"Lu177-based therapy is widely used in GEP-NETs, but unfortunately the vast majority of patients will eventually progress. Determining the optimal treatment after Lu177 has been an important question for my patients, and until now there has been no randomized Phase 3 evidence to guide it," said Simron Singh, MD, medical oncologist in the Odette Cancer Centre, Sunnybrook Health Sciences Centre, Professor of Medicine at the University of Toronto, and principal investigator of the ACTION-1 study. "ACTION-1 provides the first Phase 3 results for an alpha-based targeted RPT, and a clinically meaningful improvement in progression-free survival is a crucial development in improving the care of patients with GEP-NETs."

Individuals currently enrolled will continue to receive care consistent with the study protocol, and participants will be followed for overall survival.

About Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
GEP-NETs are rare tumors, with an estimated incidence of approximately 18,000 patients diagnosed annually in the United States and a prevalence of fewer than 200,000 patients. Somatostatin receptor type 2 (SSTR2) is expressed in 80–90% of GEP-NET tumors, and metastatic disease is present at diagnosis in the vast majority of cases. Lu177-based radiopharmaceutical therapy has shown significant clinical benefit and is approved for adult patients with SSTR-positive GEP-NETs, but most patients invariably progress following treatment, with few effective treatment options available.

About RYZ101
RYZ101 is an investigational, targeted radiopharmaceutical therapy comprised of DOTATATE bound to Actinium-225 (225Ac), a highly potent alpha-emitting radioisotope.225Ac emits a high-energy, short-range alpha particle that can cause double-stranded DNA damage in cancer cells, potentially resulting in higher chance of cancer cell death. In a Phase 1b trial of 17 previously Lu177-treated patients with disease progression, RYZ101 was well tolerated, with no treatment-related serious adverse events or dose discontinuations due to any adverse event. RYZ101 is also being evaluated in earlier-stage trials in hormone receptor-positive (HR+) metastatic breast cancer.

(Press release, Bristol-Myers Squibb, OCT 12, 2026, View Source [SID1234673325])

On October 12, 2026 Abbott reported new real-world evidence showing that completion of multitarget stool DNA (mt-sDNA) screening was associated with approximately 54% lower colorectal cancer incidence and 45% lower odds of death following a colorectal cancer diagnosis. The findings are among 13 abstracts highlighting new colorectal cancer screening research being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting, taking place Oct. 9-14 in Nashville.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New real-world evidence examines colorectal cancer incidence and mortality following Cologuard screening

Among the research presented at ACG are two large real-world studies that provide novel data regarding associations between completion of multitarget stool DNA (mt-sDNA) screening and important long-term colorectal cancer outcomes.

In a nationwide cohort of more than 2.5 million average-risk adults, researchers found that completing mt-sDNA screening was associated with an approximately 54% lower adjusted incidence rate of colorectal cancer compared with not completing the test. The association remained consistent across sensitivity analyses.

A separate population-based case-control study of 5,745 people diagnosed with colorectal cancer found that completing mt-sDNA screening within the five years before diagnosis was associated with 45% lower odds of death after diagnosis compared to those who did not complete an mt-sDNA test during that period. The association was observed across all racial and ethnic groups examined.

Together, the findings add to the growing body of real-world evidence examining longer-term outcomes associated with mt-sDNA screening, which has been used to screen for colorectal cancer more than 23 million times since the Cologuard test launched in 2014.1

"In order to achieve real public health benefits, colorectal cancer screening tests must demonstrate both high accuracy and adherence," said Paul Limburg, M.D., chief medical officer for screening, Abbott Cancer Diagnostics. "The research being presented at ACG helps us better understand what happens beyond the performance of an individual test — including whether people remain up to date with screening and how different strategies may ultimately affect colorectal cancer incidence and mortality. These insights can help us continue improving the screening experience and reach more people with the highest performing option that works for them."

Additional research emphasizes the value of mt-sDNA screening

The total research presence includes two oral presentations and 11 poster presentations spanning real-world clinical outcomes, sustained screening adherence, comparative effectiveness, test performance, health economics and patient costs. The findings add to the evidence supporting multitarget stool DNA (mt-sDNA) screening with Cologuard and Cologuard Plus and provide new insights into how colorectal cancer screening strategies perform in real-world populations.

The abstracts at ACG are as follows:

Sunday, October 11, 2026, from 3:30 to 7:00 PM

Modeling the Serrated Pathway Alters Projected Benefits of Colorectal Cancer Screening Strategies
Bayesian Analysis of CRC Sensitivity and Specificity Point Estimates for Molecularly-Based Stool Screening Tests: Influence of Data Precision on Projected Outcomes
Estimated Budget, Resource Use, and Clinical Impact of Increased Proportional Use of Next-Generation Multi-Target Stool DNA Test for CRC Screening: A US Payer Perspective
Impact of FIT Performance Variability on Long-Term Colorectal Cancer Screening Outcomes: A CRC-AIM Microsimulation Analysis
Sustained Adherence to Stool-Based Colorectal Cancer Screening: mt-sDNA vs. FIT Using Proportion of Time Up to Date
Colorectal Cancer Screening with Multitarget Stool DNA Testing: Real-World Adherence and Follow-up Colonoscopy in a Large Urban Academic Health System
Association Between mt-sDNA Completion and Reduced Colorectal Cancer Incidence: A Real-World Cohort Study
Monday, October 12, 2026, from 10:30 AM to 4:15 PM

A Longitudinal Adherence Trajectory Model for Realistic Colorectal Cancer Screening Simulation
Association of Multitarget Stool DNA Screening Completion With Reduced Odds of Death After Colorectal Cancer Diagnosis
System-Level Drivers of Incomplete At-Home Colorectal Cancer Screening: Un-Processable mt-sDNA Kits in 2025
Tuesday, October 13, 2026, from 10:30 AM to 4:00 PM

Adherence to Colorectal Cancer Screening with Screening Colonoscopy with and without Intervention: A Systematic Review and Meta-Analysis
Tuesday, October 13, 2026, Plenary Session 2A, 8:30 to 8:50 AM

Performance Characteristics of Fecal Immunochemical Tests in Males and/or Females: Should the Threshold Vary? — Oral presentation
Impact of Federal Policy Change on Patient Out-of-Pocket Costs for Follow-up Colonoscopy After Positive Stool-Based Tests— Oral presentation
For more information about Abbott’s presence at ACG 2026, click here.

About the Cologuard Plus Test

Developed in collaboration with Mayo Clinic, the FDA-approved Cologuard Plus test is a noninvasive colorectal cancer (CRC) screening option for adults aged 45 or older who are at average risk for the disease. The use-at-home test detects novel DNA biomarkers and blood in stool associated with colorectal cancer and advanced precancerous lesions, requiring no special preparation or time off to take the test. Cologuard tests have been used to screen for colon cancer millions of times.

Featuring novel biomarkers, improved laboratory processes and enhanced sample stability, the Cologuard Plus test is FDA-approved for both colon cancer and advanced precancerous lesion detection. By relying exclusively on molecular data from the patient sample, it helps support accurate results and reflects Abbott’s commitment to expanding access to colorectal cancer screening.

(Press release, Abbott, OCT 12, 2026, View Source [SID1234673324])